<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316637</url>
  </required_header>
  <id_info>
    <org_study_id>OR-ARI-EAP-NPC</org_study_id>
    <nct_id>NCT04316637</nct_id>
  </id_info>
  <brief_title>Early Access Program With Arimoclomol in US Patients With NPC</brief_title>
  <official_title>Early Access Program With Arimoclomol for the Treatment of Niemann-Pick Disease Type C in the US</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orphazyme</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orphazyme</source>
  <brief_summary>
    <textblock>
      NPC is a rare, relentlessly progressive, neurological disease and associated with serious&#xD;
      morbidity and shortened life expectancy.&#xD;
&#xD;
      The purpose of this Expanded Access Program is to provide early access to arimoclomol for&#xD;
      patients with Niemann-Pick Type C disease who, in the opinion and the clinical judgement of&#xD;
      the treating physician, may benefit from treatment with arimoclomol.&#xD;
&#xD;
      Participants will receive treatment with arimoclomol until their doctor finds it does not&#xD;
      help them anymore, they withdraw, or the study is stopped for any reason.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Niemann-Pick Disease, Type C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arimoclomol</intervention_name>
    <description>Participants receive prescribed arimoclomol by oral administration</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of NPC (NPC1 or NPC2) and at least one neurological symptom.&#xD;
&#xD;
          -  The patient is two years of age or above.&#xD;
&#xD;
          -  The patient is a permanent resident of US.&#xD;
&#xD;
          -  If taking miglustat (ZavescaÂ®), the patient must have been on the target dose for the&#xD;
             past six weeks.&#xD;
&#xD;
          -  If the patient is sexually active, it is agreed to use effective contraception.&#xD;
&#xD;
          -  Confirmed negative urine pregnancy test for sexually active female of child-bearing&#xD;
             potential (post-menarche).&#xD;
&#xD;
          -  If the patient has a history of seizures, the condition must be adequately controlled,&#xD;
             i.e., the pattern of seizure activity must be stable, and the patient must be on a&#xD;
             stable dose and regimen of antiepileptic medication during one month prior to&#xD;
             screening.&#xD;
&#xD;
          -  Patient or parent/guardian must provide written informed consent to participate in&#xD;
             EAP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe liver insufficiency.&#xD;
&#xD;
          -  Renal insufficiency.&#xD;
&#xD;
          -  Known or suspected allergy or intolerance to arimoclomol or its constituents.&#xD;
&#xD;
          -  The patient is pregnant, planning to become pregnant (while on the study) or is&#xD;
             currently breastfeeding.&#xD;
&#xD;
          -  The patient will undergo treatment with another investigational drug, whilst&#xD;
             participating in the program or in the 4 weeks prior to commencing treatment with&#xD;
             arimoclomol.&#xD;
&#xD;
          -  The patient is either eligible and able to participate in or is currently&#xD;
             participating in an active interventional clinical trial within the indication.&#xD;
&#xD;
          -  The patient, in the opinion of the clinician, is unable to comply with the treatment&#xD;
             or has a medical condition that would potentially increase the risk to the patient by&#xD;
             participation.&#xD;
&#xD;
          -  The patient has a medical condition which hinders the clinician's assessment of&#xD;
             arimoclomol safety and efficacy (e.g. certain epileptic conditions or severe&#xD;
             cataplexy).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Orphazyme Inc Medical Information</last_name>
    <phone>+1-866-696-3346</phone>
    <email>USMedInfo@orphazyme.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Clinigen Customer service</last_name>
    <phone>+1 877-768-4303</phone>
    <email>usmapoperations@clinigengroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Toni Seay</last_name>
      <phone>205-934-9508</phone>
      <email>tmseay@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joy Dean, MD</last_name>
      <phone>2059344983</phone>
      <email>joydean@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Joy Dean, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles/University of Southern California/Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Francesca Montellanos</last_name>
      <phone>323-361-5704</phone>
      <email>fmontellanos@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Alvaro H Serrano Russi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Benioff Children's Hospital and Research Center/ UCSF</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Veronica Cheung</last_name>
      <phone>510-428-3885</phone>
      <phone_ext>2752</phone_ext>
    </contact>
    <investigator>
      <last_name>Caroline Hastings, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County (CHOC)</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Nina Movsesyan, PhD</last_name>
      <phone>714-509-3008</phone>
      <email>nmovsesyan@choc.org</email>
    </contact>
    <contact_backup>
      <last_name>Raymond Wang, MD</last_name>
      <email>RaWang@choc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Raymond Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicklaus Children's Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Marinellie Vega, BA, CCRC</last_name>
      <phone>786-624-3516</phone>
      <email>marinellie.vega@nicklaushealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Dainelys Pena Rodriguez</last_name>
      <email>Dainelys.PenaRodriguez@Nicklaushealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Paula Schleifer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Ami Rosen, MS, CGC</last_name>
      <phone>404-778-8536</phone>
      <email>arosen3@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>William Wilcox, MD</last_name>
      <email>william.wilcox@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William Wilcox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Orsi Albert, MS</last_name>
      <phone>312-942-4036</phone>
      <email>Orsolya_K_Albert@rush.edu</email>
    </contact>
    <contact_backup>
      <last_name>Elizabeth Berry-Kravis, MD, PhD</last_name>
      <email>Elizabeth_Berry-Kravis@rush.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Berry-Kravis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boston Childrens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Eorna Maguire-Lobos</last_name>
      <phone>617-919-1399</phone>
      <email>Eorna.Maguire@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Olaf Bodamer, MD</last_name>
      <email>Olaf.Bodamer@childrens.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Walla Al-Hertani, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Children's Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Vanessa Morrow</last_name>
      <phone>507-538-0266</phone>
      <email>morrow.vanessa@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Marc Patterson, MD</last_name>
      <email>Patterson.Marc@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marc Patterson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Claire MIller, MD</last_name>
      <phone>212-263-7744</phone>
      <email>claire.miller@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Danika Anganoo-Khan</last_name>
      <phone>929-455-5629</phone>
      <email>Danika.Anganoo-Khan@nyulangone.org</email>
    </contact_backup>
    <investigator>
      <last_name>Claire Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Lisa Berry, LGC</last_name>
      <phone>800-647-4805</phone>
      <email>Lisa.Berry@cchmc.org</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Kahler</last_name>
      <phone>513-636-9938</phone>
      <email>Melissa.Kahler@cchmc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Loren Pena, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Can Ficicioglu, MD, PhD</last_name>
      <phone>215-590-3376</phone>
      <email>FICICIOGLU@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Emily Nolasco-Barrientos, MPH</last_name>
      <phone>657-549-2423</phone>
      <email>nolascobae@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Can Ficicioglu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Nadene Hendersen</last_name>
      <phone>412-692-6378</phone>
      <email>Nadene.Hendersen@chp.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kaylee Williams</last_name>
      <phone>412-692-8413</phone>
      <email>williamsk38@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Damara Ortiz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dell Children's Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Kendra Koch, PhD</last_name>
      <phone>512-785-4442</phone>
      <email>kdkoch@utexas.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karla Robles-Lopez</last_name>
      <phone>346-370-7735</phone>
      <email>karla.robleslopez@austin.utexas.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kristina Julich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Health / McGovern Medical School; Division of Medical Genetics</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
    <contact>
      <last_name>Heather Saavedra, MS, RD, LD</last_name>
      <phone>713-500-7098</phone>
      <email>Heather.Saavedra@uth.tmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ify Ibekwe</last_name>
      <phone>713-500-5064</phone>
      <email>Ifeoma.C.Ibekwe@uth.tmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Hillman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Niemann-Pick Diseases</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type A</mesh_term>
    <mesh_term>Niemann-Pick Disease, Type C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

